How NIH Cuts Could Affect U.S. Biomedical Research

IRA FLATOW: This is Science Friday. I’m Ira Flatow. One of President Trump’s targets for cutting has been the National Institutes of Health, including layoffs of some 1,200 NIH employees, termination of research grants, and an order capping indirect costs to grants. Some of these moves have been paused following court cases, but they are still an ongoing topic of concern.

Joining me now to talk about how the NIH operates, what the new administration changes could mean for medical research in this country is Dr. Harold Varmus. He was Director of the NIH from 1993 to 1999, currently Professor of Medicine at Weill Cornell Medicine, and Senior Associate at the New York Genome Center and the 1989 Nobel Prize winner in medicine. Welcome back to Science Friday.

HAROLD VARMUS: Thank you, Ira. Good to see you.

IRA FLATOW: Nice to see you. Last month, you wrote an op-ed for The New York Times entitled, “I Used to Run the N.I.H. Here’s What Worries Me.” I mean, tell us how you would characterize what worries you, what’s being done to the NIH?

HAROLD VARMUS: Well, there are a number of things that are concerning me at the moment. One is the general threat to science, which is one of the prides of our country and a way to solve some of the biggest problems that face our citizens. The other is the threat to investigators who’ve spent their lives training to do these jobs, and especially in the public sector, who are now being threatened with loss of their grant funds, hold-ups in the way the research is being pursued, slowdowns in the grant review process at a time when we already have a highly competitive atmosphere in which grants are being awarded, the appointment of leaders who, in my view, are inadequate to the task of running the major agencies– not just the NIH, but also the CDC and the Department of Health and Human Services itself, which oversees the health research agencies.

So there are many ways in which scientists who do biomedical research, either clinical research or basic research, are feeling threatened. They don’t feel they get support of the kind that they need from the public, and importantly, from the industries, biotech and pharmaceutical industries that are so dependent on the research that’s generated by these people.

IRA FLATOW: Mm-hmm. I mean, as head of NIH for, what, six years, and head of the National Cancer Institute, you’re sort of watching attempts at dismantling your whole life’s work.

HAROLD VARMUS: You know, there is incredible amounts more to be done. A lot has been accomplished, but a lot more to be done. And the one way not to get it done right is to have poor leadership, undue restrictions on what can and can’t be done, discouragement to young people who either– people growing up in the US or people from abroad who have traditionally brought so much to our science. If I were thinking about a career in biomedical science today, and I’d been brought up in Asia or South America or anyplace else, I would say, there are a lot of other places than the US to do this kind of work.

IRA FLATOW: And in last month’s Times op-ed piece, you said you were troubled that there hadn’t been big protests so far. Yet last week there were big Stand Up for Science events. Does that give you some hope?

HAROLD VARMUS: Well, yes. I mean, I definitely was pleased to see, and in fact, participated in the event in New York and in Washington Square Park. And it was good to see many of my colleagues and students and other trainees and members of the public out in reasonably large numbers.

Friday’s demonstrations were evidence that there is going to be some public outcry. More outcries will be needed, and people need to recognize that we all want America to be successful, and we all want scientists to be able to do their work and the things that are being enforced on our community at the moment, through actions taken through the NIH and through the general negativity that is so prominent in public pronouncements, is going to damage science over a very long haul.

IRA FLATOW: Do you think the public realizes this? Not me.

HAROLD VARMUS: Not sufficiently yet. I mean, it depends a little bit on how you ask the question. Do people want medical research to produce cures for the illnesses they’re worried about? Of course. But they need to be able to understand what the significance of some of the budgetary cuts might be, and the kinds of draconian measures that are being proposed by this new organization called DOGE are not going to cure the financial ills of the country– that, in fact, investments in medical research enrich our economy.

Every dollar spent on the NIH produces additional commercial activity of various kinds that help our country become wealthier, not poorer. And you’re not going to end the trillion-dollar deficits that our country is experiencing by making a million or even billion dollar cuts in NIH spending. It’s a very poor thing to cut.

I’m particularly troubled by something we haven’t mentioned yet, which is the idea that America can go it alone, and of course, going it alone while we’re cutting back on the support is a problem. But you have to realize that science is an international activity and that public health is done best when we’re in communication with many other countries. The attempt to dismantle USAID, the Agency for International Development, and the withdrawal from the World Health Organization, these are devastating steps that are going to be detrimental to health everywhere in the world, and detrimental to our reputation as well.

IRA FLATOW: Mm-hmm. So you view those as real possibilities– the consequences, I guess I should say, when the next epidemic comes around.

HAROLD VARMUS: Well, you know, we’re worried about epidemics all the time. There are indications that we may be facing a bird flu epidemic. There’s always the possibility of another coronavirus outbreak. There are other diseases that are much less common. But like Marburg disease and quite a few others that are seen sporadically, we’re trying to bring polio to a halt, and the public is not sufficiently responsive, in my view, to the dreadful effects of having the US pull out of the World Health Organization.

IRA FLATOW: Many of the DOGE actions have been billed as, we need to tighten our belts. We need to cut out the waste. I mean, are there places you think that NIH could operate more efficiently?

HAROLD VARMUS: Well, look, every organization has room for improvement. And like everyone I in the senior ranks of NIH-supported investigators, I’ve been critical of the NIH for some of the ways it does things. But on the whole, it’s an efficient, incredibly successful agency that remains one of the jewels in the crown of US government. Of course, we can save some dollars, but the kind of large scale economic constraints that we need to take if we’re going to avoid our trillion-dollar, multi-trillion dollar debt are not going to be gained by lopping a few million or even a few billion out of the NIH.

IRA FLATOW: Mm-hmm. What do you think of Trump’s pick to head the NIH, Dr. Bhattacharya?

HAROLD VARMUS: Well, he’s not somebody I know particularly well, and I’m not opposed to him because of his being fundamentally a health economist. He is an MD, and I think he’s an intelligent person. But he’s done several things in the past that make me concerned about his ability to run an organization that is so deeply involved in the kind of research that he’s really not familiar with.

I’m also concerned about the emphasis he’s placing on the question of free speech as a criterion for determining who gets funded. I think what he means by free speech is that he wants to be able to say whatever he pleases without having anybody criticize him.

IRA FLATOW: Do you think that the wounds that NIH and the research community might suffer during this administration would be permanent, to take years to recover from?

HAROLD VARMUS: Well, they don’t need to be permanent. But I welcome your comment, Ira, because people need to realize that although we now have an incredibly successful, federally-supported scientific enterprise in this country, it took a long time to get there. The US was not a prominent player in science until after World War II, when Franklin Roosevelt’s science advisor, Vannevar Bush made a plan for how the federal government could support basic science, produce results that would be available for commercial development, and through grants to investigators working at our academic institutions. That had a tremendous amount to do with the tremendous success of our universities in supporting the training of scientists and the conduct of science with federal dollars.

Now we are the envy of the world for having developed a system that is so highly functional. But over the course of just a couple of years, it’s very easy to deplete these institutions of not just the resources, but the people and the talents that have fueled all of our success. The proposals that were made abruptly and recently to remove what is somewhat irresponsibly called indirect cost, the absolutely essential funding for facilities and administrative support for science, could be in a very short time, deeply, deeply destructive to the enterprise that we’ve built up. And it could take decades, not years, to restore some of that.

IRA FLATOW: Mm-hmm. Do you think we might be seeing a brain drain, as we used to call it, of researchers going to other countries?

HAROLD VARMUS: Well, you don’t even have to go to another country to become a brain drain. Many who have been working in the scientific enterprise and in the not-for-profit sector could very easily find other kinds of occupations that might be in science or outside of science, tremendous loss of talent and waste of investment in training these individuals. And that is part of the destruction of the system that worries me the most.

But the job market’s already very tight. There are jobs in industry. You have a great need for better science teachers in our public schools. I mean, there are jobs, but I think I’m less worried about where people will go for another job than I am about the loss of talent in a domain in which not only is the US so successful and dominant, but a place where great science remains to be done, and the science is beneficial to society.

I do think that people are understandably naive about what it means to have money going into research. Well, companies do extremely little in basic research, and yet most of the ideas that fuel the dramatic new changes in medical care, for example, on the one hand, dependent on development of those therapies in industry, are fundamentally dependent on the new ideas that arise out of federally supported basic research at universities.

Take, for example, the excitement in my own field about immunotherapies for cancer. That’s a result of investments in scientists working at places like UC Berkeley or Memorial Sloan Kettering in a deeper understanding of the immune system. So it was possible to begin to understand how you could develop immunological tools for treating cancer. That’s not going to happen if we disassemble the federally supported machine that’s been so effective in deepening our understanding of how bodies respond to the various diseases that we call cancers.

IRA FLATOW: You don’t even have to go that deeply. You can get into something that everybody knows about– Ozempic, the GLP-1 receptor drugs, weren’t they all NIH?

HAROLD VARMUS: Well, originally, yes. It all came from trying to understand appetite and obesity. Absolutely. But there are many, many examples. Immunotherapy for cancer is one of them. But there are many, many others that involve investment in fundamental research. That’s the real investment that the federal government makes in industry.

It makes this investment that was originally conceived by Vannevar Bush during World War II, that when you make investments in really understanding the world, you generate new ideas about how the world works, that the industry is pretty good at transforming into practical solutions to our world problems. And not just in health, but in security and arms and manufacturing, and in making life pleasurable.

IRA FLATOW: This is Science Friday from WNYC Studios. If you’re just joining us, I’m talking with Dr. Harold Varmus, former head of the National Institutes of Health, about changes to biomedical research under the Trump administration. So where do you see possible pushback, compromise, solutions? Is it court orders, congressional action, people protesting?

HAROLD VARMUS: Critical question, Ira. And I’m glad we’re getting around to this, because one of the things I’ve been concerned about is the balance of power between the executive and legislative branch is eroding at the moment, and the legislators are not standing up. Many of the people I see making decisions about who should be confirmed for leadership positions, who should be exerting their power as members of Congress to say these things are violations of laws we’ve already passed, for example, laws about how we pay for research through payment of facilities and administrative costs, as well as direct costs of research.

Congress needs to step up. Right now, we’re placing our biggest bets on resistance from the judiciary branch, which has stood up to several of the efforts that the executive branch has been making to disassemble and undermine research. But that’s not enough. We need Congress to be speaking up as well, and people who are experienced and knowledgeable and have been responsive to the needs of the scientific community over the past several decades, need to set aside their apprehensions about their own reelection and stand up for what’s right.

It’s got to come from patients, their families, advocates, from members of industries that are dependent on government-sponsored research for the kinds of advances they make that are profitable for them in the long run. And from the general public, which sees one of the great virtues of our country, our service is a beacon for people around the world, talent in our own country to participate in these great adventures of scientific discovery that have been so beneficial to the world and to our own economy.

IRA FLATOW: I mean, you’ve been around a while. I mean, have you ever seen such politicalization?

HAROLD VARMUS: I mean, I’ve been very pleased as a leader of the NCI or the NIH, to have friends on both sides of the aisle and to see Republicans and Democrats supporting scientific activity. And that’s been a wonderful aspect of being in the government through work on something which is supported by both parties. And right now, the alignment of politicians with these attacks on science is deeply disturbing to me. It’s a long-lasting effort to politicize science. That is something that I think will be not so easy to reverse.

IRA FLATOW: No. And I think you’ve summed it up very well, Dr. Varmus. And I want to thank you for taking time to be with us today.

HAROLD VARMUS: My pleasure. Always good to talk to you, Ira.

IRA FLATOW: Dr. Harold Varmus, former director of the NIH, currently the Lewis Thomas University Professor of Medicine at Weill Cornell Medicine.

Copyright © 2025 Science Friday Initiative. All rights reserved. Science Friday transcripts are produced on a tight deadline by 3Play Media. Fidelity to the original aired/published audio or video file might vary, and text might be updated or amended in the future. For the authoritative record of Science Friday’s programming, please visit the original aired/published recording. For terms of use and more information, visit our policies pages at http://www.sciencefriday.com/about/policies/